Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]Afuresertib in Healthy Chinese Male Adults
NCT05489744Phase 1Completed
- Sponsor
- Laekna
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afuresertib in breast cancer, prostate cancer (PCa), ovarian cancer and 1 more, sponsored by Laekna. Primary endpoints: Quantitatively analyze total radioactivity in the excreta, Pharmacokinetics (PK) analysis of radioactivity in plasma and 2 more. Started Aug 2022; status: completed.
02
Drugs
afuresertib
03
Conditions
breast cancerprostate cancer (PCa)ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT05489744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489744.